Skip to main content

Immunostimulatory Agonist antibodies for Cancer Therapy

Objective

"This concerted action aims at providing new treatment options for cancer patients through boosting innovative drug development by European academia and industry. A wealth of preclinical data shows that the therapeutic impact of cytotoxic regimens is enhanced by simultaneous application of drugs that strengthen the immune system. The recent FDA-approval of Ipilimumab demonstrated that cancer immunotherapeutics constitute a clinically effective, marketable drug concept. Ipilimumab is an antagonist immunostimulatory antibody (IS-Ab) that removes the restraint on the immune response by blocking inhibitory receptors on immune cells. Potent immunity can also be elicited by means of agonist IS-Abs that engage activatory receptors. Our program will translate the agonist IS-Ab concept into clinical treatments. This is critical, because a repertoire of complementary drugs that act at different points in the immune regulatory network will be required to counter immune failure in different cancer (sub-)types.
Our initiative is supported by longstanding experience as well as by the availability of clinical lead Abs. Pivotal are two clinical trials in which cancer type and treatment regimen have been selected to approximate pre-clinical settings in which striking therapeutic impact with agonist IS-Abs has been obtained. These studies will involve extensive analysis of efficacy-related biomarkers by means of validated assays, not only in blood samples, but also in the most relevant compartment: the tumor microenvironment. While our state-of-the-art agonist IS-Abs are being tested in the clinic, a parallel SME-driven effort will aim at the development of 2nd generation agonist IS-Abs with superior therapeutic index. This innovation is supported by proprietary technology and will result in intellectual property and marketable drugs. Taken together, our interdisciplinary platform is designed to yield maximal benefit for health care, academia and health-related industries in Europe."

Call for proposal

FP7-HEALTH-2013-INNOVATION-1
See other projects for this call

Coordinator

DEUTSCHES KREBSFORSCHUNGSZENTRUM HEIDELBERG
Address
Im Neuenheimer Feld 280
69120 Heidelberg
Germany
Activity type
Research Organisations
EU contribution
€ 363 973
Administrative Contact
Rienk Offringa (Prof.)

Participants (9)

UNIVERSITATSKLINIKUM HEIDELBERG
Germany
EU contribution
€ 981 860
Address
Im Neuenheimer Feld 672
69120 Heidelberg
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Thorsten Brietz (Mr.)
UNIVERSITY OF SOUTHAMPTON
United Kingdom
EU contribution
€ 1 295 820
Address
Highfield
SO17 1BJ Southampton
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Yan Qiao (Ms.)
FUNDACION PARA LA INVESTIGACION MEDICA APLICADA FIMA
Spain
EU contribution
€ 306 304
Address
Avenida De Pio Xii 55
31008 Pamplona
Activity type
Research Organisations
Administrative Contact
Ana Iglesias Garcia (Ms.)
UNIVERSIDAD DE NAVARRA
Spain
EU contribution
€ 299 600
Address
Campus Universitario Edificio Central
31080 Pamplona
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Fco. Javier Irigoyen Barrio (Mr.)
FONDAZIONE IRCCS ISTITUTO NAZIONALE DEI TUMORI
Italy
EU contribution
€ 306 500
Address
Via Venezian 1
20133 Milan
Activity type
Research Organisations
Administrative Contact
Antonio Cannarozzo (Dr.)
GLYCOTOPE GMBH
Germany
EU contribution
€ 448 426
Address
Robert Rossle Strasse 10
13125 Berlin
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Hans Baumeister (Dr.)
BIOINVENT INTERNATIONAL AB
Sweden
EU contribution
€ 448 399
Address
Soelvegatan 41
22370 Lund
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Titti Niskanen (Dr.)
LEADARTIS S.L.
Spain
EU contribution
€ 448 465
Address
Calle Ferraz 3 1 Izq
28005 Madrid
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Laura Sanz Alcober (Dr.)
BIONTECH RNA PHARMACEUTICALS GMBH
Germany
EU contribution
€ 1 096 400
Address
An Der Goldgrube 12
55131 Mainz
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Ugur Sahin (Prof.)